Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ixazomib + thalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Ixazomib + thalidomide + dexamethasone is an all-oral combination regimen used primarily for the treatment of relapsed or refractory multiple myeloma. Ixazomib is a small molecule proteasome inhibitor that disrupts protein degradation in cancer cells, leading to apoptosis. Thalidomide acts as an immunomodulatory agent, binding to cereblon and promoting the degradation of transcription factors IKZF1 and IKZF3, which are essential for myeloma cell survival. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and cytotoxic effects on lymphoid cells, enhancing the efficacy of the other agents. This combination has demonstrated clinical activity and tolerability in patients who have received prior therapies for multiple myeloma[1][3][4][8].
- Brand names
- Ninlaro (for ixazomib)Thalomid (for thalidomide)Decadron (for dexamethasone)
- Other names
- ITdIxaThalDex
02
Targets
GR (Glucocorticoid receptor)CRBN (Cereblon)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on ixazomib + thalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ixazomib + thalidomide + dexamethasone.